| 000 | 01845cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030623.0 | ||
| 008 | 120515s2012 ua d f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.08.08.M.Sc.2012.Do.C | ||
| 100 | 0 | _aDoaa Hamed Abdelaziz Yousef Ali | |
| 245 | 1 | 2 |
_aA clinical pharmacokinetic study on the use of pegylated interferon in Egyptian children infected with hepatitis C / _cDoaa Hamed Abdelaziz Yousef Ali ; Supervised Omaima N. Elgazayerly , Manal H. Elsayed , Nirmeen A. Sabry |
| 246 | 1 | 5 | _aدراسة حركية الدواء الإكلينيكية لعقار الإنترفيرون طويل المفعول فى الأطفال المصريين المصابين بالإلتهاب الكبدى الفيروسى سى |
| 260 |
_aCairo : _bDoaa Hamed Abdelaziz Yousef Ali , _c2012 |
||
| 300 |
_a144 P. : _bcharts ; _c25cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics | ||
| 520 | _aThe aim of this study is to clarify the pharmacokinetic profiles of pegylated interferon therapy (PEG-IFN - Ü- 2a (20 kDa)) in Egyptian HCV infected children and adolescents as well as determining the efficacy and safety of PEG - IFN / Ribavirin combination therapy . Thirty patients were recruited according to specific inclusion and exclusion criteria | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aChronic hepatitis C | |
| 653 | 4 | _aPegylated interferon | |
| 653 | 4 | _aRibavirin | |
| 700 | 0 |
_aManal Hamdy Elsayed , _eSupervisor |
|
| 700 | 0 |
_aNirmeen Ahmed Sabry , _eSupervisor |
|
| 700 | 0 |
_aOmaima Naeem Elgazayerly , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aFatma _eCataloger |
||
| 905 |
_aNazla _eRevisor |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c38506 _d38506 |
||